{"id":18719,"date":"2022-02-23T07:19:45","date_gmt":"2022-02-23T15:19:45","guid":{"rendered":"https:\/\/marketdepth.com\/?p=18719"},"modified":"2022-02-23T07:19:48","modified_gmt":"2022-02-23T15:19:48","slug":"kodiak-sciences-plummets-after-disappointing-phase-2b_3-results","status":"publish","type":"post","link":"https:\/\/marketdepth.com\/kodiak-sciences-plummets-after-disappointing-phase-2b_3-results\/","title":{"rendered":"Kodiak Sciences Plummets After Disappointing Phase 2b_3 Results"},"content":{"rendered":"\n
Kodiak Sciences Inc. (Nasdaq: KOD)<\/strong> announced <\/a>today that its Phase 2b\/3 study of KSI-301 had failed to meet the primary endpoint.<\/p>\n\n\n\n Shares of Kodiak Sciences Inc. (Nasdaq: KOD) plummeted 78% following the announcement.\u00a0<\/p>\n\n\n\n Its study of KSI-301, a novel antibody biopolymer conjugate, in treatment-na\u00efve subjects with neovascular age-related macular degeneration included 559 participants, approximately 80% of whom were enrolled in the United States.<\/p>\n\n\n\n Despite KSI-301 demonstrating strong durability as well as safety and tolerability, it did not meet the primary efficacy endpoint of showing non-inferior visual acuity gains for subjects dosed on extended regimens compared to aflibercept given every eight weeks, according to the company\u2019s press release.<\/p>\n\n\n\n “Allowing treatment with KSI-301 no more often than every 12 weeks after the loading phase for every patient turned out to be insufficient.”<\/p>Victor Perlroth, MD, Kodiak’s Chief Executive Officer<\/cite><\/blockquote>\n\n\n\n Dr. Carl Regillo, MD, Chief of the Retina Service at Wills Eye Hospital in Philadelphia and a study investigator, added, “We learned that the study design stretched it too far for the roughly 30% of patients who could have benefited from more VEGF inhibition than the minimal every 3 months in the study.\u201d<\/p>\n\n\n\n Full results from the study are expected to be presented at a future medical symposium.<\/p>\n","protected":false},"excerpt":{"rendered":"Kodiak Sciences Inc. (Nasdaq: KOD) announced today that its Phase 2b\/3 study of KSI-301 had failed to meet the primary endpoint. Shares Plummeted Shares of Kodiak Sciences Inc. (Nasdaq: KOD) plummeted 78% following the announcement.\u00a0 80% In USA Its study of KSI-301, a novel antibody biopolymer conjugate, in treatment-na\u00efve subjects with neovascular age-related macular degeneration… View Article<\/a>","protected":false},"author":3,"featured_media":17641,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":0,"footnotes":""},"categories":[9,31,17,8,11,16],"tags":[],"acf":[],"yoast_head":"\nShares Plummeted<\/h5>\n\n\n\n
80% In USA<\/h5>\n\n\n\n
Efficacy Missed<\/h5>\n\n\n\n